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Abstract
Background: Individuals at risk of rheumatoid arthritis (RA) demonstrate systemic autoimmunity in the form of
anti-citrullinated peptide antibodies (ACPA). MicroRNAs (miRNAs) are implicated in established RA. This study aimed
to (1) compare miRNA expression between healthy individuals and those at risk of and those that develop RA, (2)
evaluate the change in expression of miRNA from “at-risk” to early RA and (3) explore whether these miRNAs could
inform a signature predictive of progression from “at-risk” to RA.
Methods: We performed global profiling of 754 miRNAs per patient on a matched serum sample cohort of 12
anti-cyclic citrullinated peptide (CCP) + “at-risk” individuals that progressed to RA. Each individual had a serum sample
from baseline and at time of detection of synovitis, forming the matched element. Healthy controls were also studied.
miRNAs with a fold difference/fold change of four in expression level met our primary criterion for selection as
candidate miRNAs. Validation of the miRNAs of interest was conducted using custom miRNA array cards on matched
samples (baseline and follow up) in 24 CCP+ individuals; 12 RA progressors and 12 RA non-progressors.
Results: We report on the first study to use matched serum samples and a comprehensive miRNA array approach
to identify in particular, three miRNAs (miR-22, miR-486-3p, and miR-382) associated with progression from systemic
autoimmunity to RA inflammation. MiR-22 demonstrated significant fold difference between progressors and
non-progressors indicating a potential biomarker role for at-risk individuals.
Conclusions: This first study using a cohort with matched serum samples provides important mechanistic insights in
the transition from systemic autoimmunity to inflammatory disease for future investigation, and with further evaluation,
might also serve as a predictive biomarker.
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Background
Individuals at risk of rheumatoid arthritis (RA) or pre-
clinical RA [1, 2] are characterised by the presence of
systemic autoimmunity in the form of highly specific
anti-citrullinated peptide antibodies (ACPAs) with or
without rheumatoid factor (RF) [3]. Increasing research
efforts are focusing on tools to identify those at highest
risk of progression to RA in whom immunomodulatory
therapy could be used as a preventative strategy [4]. We
have previously reported on an at-risk cohort defined by
the presence of anti-cyclic citrullinated peptide (CCP)
antibody and non-specific musculoskeletal (MSK) symp-
toms [5] in whom progression to inflammatory arthritis
(IA) occurred in 50%, after a median of 7.9 months
(range 0.1–52.4), 34% within 12 months.
MicroRNAs (miRNAs) are a highly conserved class of
short non-coding RNAs that serve as transcriptional
negative regulators [6]. A number of studies have
demonstrated dysregulated miRNA expression within
the inflamed joints of patients with RA, with in par-
ticular, evidence for miR-146a and miR-155 upregulation
[7, 8]. Such studies to date, however, have focused on
the established phase of RA. Arguably, alternative
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additional miRNAs might be relevant in driving a state
of autoimmunity to disease i.e. at the time of disease
initiation. No miRNA study to date has focused on indi-
viduals at risk of RA.
We took a unique approach of using samples from in-
dividuals identified as being at risk and a further sample
at the time of their development to RA; first, to compare
miRNA expression between health and individuals at
risk of RA, and those that develop RA; second, to
evaluate for any change in expression of the identified
miRNAs with progression along the RA continuum and
third, to explore whether these miRNAs could inform a
signature predictive of progression from systemic auto-
immunity to RA for future evaluation.
Methods
Study design and participants
Prospective CCP cohort study
Since 2007, patients ≥ 18 years of age presenting to pri-
mary care services in Yorkshire (UK) with any new,
non-specific, MSK symptom(s), who test positive for
anti-CCP (CCP+) have been invited to attend regular as-
sessments at the research clinic at Chapel Allerton
Hospital, Leeds (UK), as part of the prospective CCP
study. The CCP study is sponsored by the University of
Leeds, approved by the appropriate research ethics com-
mittee (REC; reference 06/Q1205/169). All patients pro-
vided written informed consent for the study.
Patient assessments
All patients recruited to the CCP study are assessed at
baseline, 3-monthly intervals for the first year, and then
as clinically indicated and/or until they developed in-
flammatory arthritis (IA); defined by the presence of at
least one tender and swollen joint confirmed by a
rheumatologist. Rheumatologists, trained in the assess-
ment of IA, carry out the clinical assessments. Blood
sampling and power Doppler ultrasound scan of the
hands and feet are performed at baseline and then at
regular intervals until the development of IA. The ultra-
sound examination was performed on all patients by a
single rheumatologist (JLN) experienced in MSK ultra-
sound. Patients recruited to the study had scans of the
wrists, metacarpophalangeal joints (MCPs), proximal
interphalangeal joints (PIPs) and metatarsophalangeal
joints (MTPs) bilaterally (as well as any other joints if
symptomatic). We and others have previously demon-
strated the presence of synovitis on ultrasound [9]. CCP
+ at-risk individuals with ultrasound-identified synovitis
(defined as power Doppler signal) of the aforementioned
small joints were excluded, as this was considered to be
too close to RA on a pathological level. Selection of
individuals for our miRNA profiling study was from this
at-risk, CCP+ cohort.
Pilot and validation-phase patient cohorts
From our at-risk cohort, 12 CCP+ patients who pro-
gressed to RA (American College of Rheumatology
(ACR)/European League Against Rheumatism (EULAR)
2010 criteria), termed very early RA (VERA) were avail-
able as per the criteria described earlier and selected.
Each patient had a blood sample taken at baseline and at
the time of detection of synovitis, forming the matched
element of this analysis. Twelve healthy controls (HC)
were identified via our “ask a friend” approach, tested
for and confirmed to be anti-CCP negative, and subse-
quently also included.
To validate the findings, a further 12 CCP+ patients
who progressed to VERA (progressors) and had a
matched blood sample available at detection of synovitis
were identified. A comparator group consisting of the
available 12 CCP+ individuals who did not progress to
VERA (non-progressors) and for whom samples were
available, were also selected, with a matched sample
used 36 weeks after baseline. The 36-week time point
was selected following pilot-phase data, indicating a
median time to progression to synovitis of 34.5 weeks,
enabling a closely matched sample point between the
two groups. A further 12 HC were studied. Thus, the
validation phase included an identical group to that in
the pilot phase and an additional comparator group to
enable us to determine whether the miRNAs identified
were unique to the development of VERA. Additional
file 1 illustrates patient characteristics for the pilot and
validation phases.
Isolation and profiling of serum miRNA
Serum microRNAs were isolated according to the manu-
facturer’s protocol using miRNeasy serum plasma kit
(Qiagen, UK). For complementary DNA (cDNA) synthe-
sis, Taqman miRNA reverse transcription kit was used
(Life Technologies), 3 μl RNA input isolated from serum
with Megaplex primer pools Human set v3.0 A and B
(Life Technologies) separately. Pre-amplification reac-
tions were performed following manufacturer’s protocol
using Taqman pre-amplification mastermix, Taqman
array human miRNA A and B (Life Technologies). Un-
diluted pre-amplification product was prepared in a
mastermix with Taqman universal mastermix II no UNG
and water and loaded into Taqman Low Density TLDA
microRNA cards A v3.0 and B set v2.0 (Life Technologies)
on an Applied Biosystems 7900HT fast real-time system.
See Additional file 2 for detailed methods.
Quantitative reverse transcription (qRT)-PCR on custom
miRNA cards
The validation phase was carried out using quantification
of the expression of miRNAs of interest using TLDA cus-
tom cards (31 candidate miRNAs), and RNU6B was used
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as control for normalisation as recommended by the
manufacturer. Expression profiles of RNU6B were stable
across all samples with cycle threshold (Ct) values ranging
between 23 and 26. Extraction of serum RNA was as
described above (detailed method in Additional file 2).
Custom primers for the selected miRNAs were used for
reverse transcription and pre-amplification steps. Expres-
sion of each miRNA and control was measured in tripli-
cates, and four samples could be included on each card;
baseline and follow-up samples for pairs of patients were
therefore assigned to the cards. For each individual sample
the mean of the three endogenous control replicates was
used to normalise values for each of the three replicates
per miRNA, then the mean delta Ct (dCt) per miRNA
was taken.
miRNAs network analysis
MetaCore™, an extensively used integrated software suite
(Thompson Reuters, New York, NY, USA) used for the
functional analysis of high-throughput data including
microRNA, and based on MetaBase [10, 11] was used
for the network analysis.
Statistical analysis
For both phases, we used a rule of thumb of n = 12 per
group for pilot studies [12]. As appropriate for pilot
studies, the extent of descriptive differences rather than
inferential testing (and use of p values) was applied. For
between-group comparisons, quantile regression, adjust-
ing for age, was used to obtain adjusted between-group
differences in median dCt, which was converted to fold
difference (FD) (2-ddCt). For within-patient changes, ddCt
was calculated then median ddCt was calculated at the
group level and converted to fold change (FC). If FD or FC
was < 1, -1/(value) was calculated. Fold differences were
calculated as 2-(dCt (progressors)-dCt (non-progressors)).
Fold changes were calculated as 2-(dCt (follow-up)-dCt
(baseline)). In either case, if the value was < 1, it was trans-
formed to -1/FD (or -1/FC as appropriate). Negative values
therefore indicate that expression was lower in progressors
compared to non-progressors (negative FD), or lower at
follow up compared to baseline (negative FC).
To identify the most dysregulated miRNAs to take into
the validation phase, particularly stringent criteria were ap-
plied of |FD| or |FC| ≥ 4, irrespective of statistical signifi-
cance, and within progressors, we additionally required the
direction of change to be consistent in ≥ 75% of patients.
Association with clinical variables was assessed using
Spearman’s rank. Area under the receiver operating
characteristic (ROC) curve for classifying progressors/non-
progressors was calculated for each miRNA. Sensitivity/
specificity was calculated at the point that maximised
the Youden index (sensitivity + specificity-1). In the val-
idation phase undetermined Ct values were imputed
prior to analysis (see Additional file 2). GraphPad Prism
5, R and SPSS v.21 software packages were used.
Results
Patient cohorts - progression from CCP+ status to VERA
CCP+ patients (n = 136) with non-specific MSK symp-
toms were recruited to the prospective “at-risk” clinic:
57 patients progressed to VERA after a median (range)
of 8.6 months (0.1–52.4). Of those 57 patients, 29 had
no ultrasound-detectable synovitis (including in symptom-
atic joints) at baseline; of these, 12 available individuals
were selected for the pilot phase. A further available 24
patients (12 who progressed to RA and 12 who did not)
were selected for the validation phase (Additional file 1).
Pilot phase of serum miRNA profiling
Of the 754 human miRNAs accurately quantified, a num-
ber were observed to have different expression profiles be-
tween the cohorts. As detailed earlier, the primary
criterion for selection of miRNAs of interest was a FD/FC
of 4 in expression level (FD/FC ≥4); for within-patient
change (CCP+ status to VERA) we also required a pattern
of dysregulation consistent across ≥ 75% of the cohort.
A list of miRNAs of interest was established (Table 1)
comprising all dysregulated miRNAs across the three
studied cohorts (19 in total), 9 miRNAs (miR-21, miR-
146a, miR-155, miR-18a, miR-34a, miR-203, miR-223,
miR-16, miR-132) that have been demonstrated to be in-
volved in the pathogenesis in RA from the literature [13]
and 2 miRNAs (miR-15#, miR-335#) that started to be
expressed as patients progressed from CCP to VERA. Fol-
lowing adjustment for age, 2 of these miRNAs (miR-374
and miR-454) no longer had an FD >4 but were still in-
cluded in the final 31 miRNAs of interest.
HC-CCP+ and HC-VERA comparison
Between the HC and CCP+ group 7 dysregulated miRNAs
were identified (4 downregulated and 3 upregulated); be-
tween the HC and (matched CCP+ status to) VERA cohort,
13 dysregulated miRNAs were recorded (12 upregulated, 1
downregulated) (Table 1). As stated previously, these
miRNAs, plus nine miRNAs that have been demonstrated
in the literature to be involved in the pathogenesis in RA,
informed the tailored array cards used for investigation of
miRNA profiles from CCP+ to VERA.
Matched CCP+ to VERA serum miRNA evaluation
Unsupervised hierarchical clustering of the global ex-
pression profiles of 31 miRNAs of interest was generated
using complete linkage (Fig. 1a). From paired analysis of
the matched samples, three circulating miRNAs were
upregulated upon progression from CCP+ status to
VERA (Fig. 1b). Serum miR-22 expression increased the
most in patients from CCP+ status to VERA (median FC
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4.3 (IQR 2.8, 12.1); expression increased in all patients).
There was comparable upregulation for miR-382 (4.1 (1.7,
6.9); increased in 11/12) and miR-486-3p (4.1 (0.9, 8.6; in-
creased in 9/12) (Table 1). Since miR-146a and miR-155
are the most commonly reported miRNAs to be dys-
regulated in RA, we investigated their expression in the
matched serum samples. Both were upregulated in the
majority (8/12) of the individuals who progressed to RA
Table 1 List of miRNAs of interest with age-adjusted FD ≥4 between the three studied cohorts in the pilot phase ( upregulated
FC ≥4, downregulated FC ≤ -4)
HC CCP VERA CCP vs. HC VERA vs. HC CCP to VERA (within progressors)




Median (IQR) ddCt Median FC Number
upregulated (/12)
miR-16 -6.3 (-7.1, -6.0) -7.1 (-7.6, -7.0) -7.6 (-8.2, -7.4) 1.7 2.4 -0.4 (-1.1, -0.1) 1.3 10
miR-18a 0.1 (-0.8, 1.3) 1.3 (0.3, 2.0) -0.1 (-1.0, 0.4) -2.4 1.1 -1.6 (-2.0, -1.0) 3.1 10
miR-19a -0.9 (-1.6, 1.0) -2.4 (-2.8, -1.9) -3.2 (-3.5, -2.8) 2.9 5.0 -0.6 (-1.7, 0.1) 1.5 9
miR-21 -2.8 (-4.1, -2.5) -3.8 (-4.4, -3.3) -4.3 (-4.8, -4.1) 2.0 2.7 -0.7 (-1.2, -0.2) 1.6 9
miR-22 4.2 (0.5, 4.8) 3.0 (1.5, 5.1) 0.9 (0.6, 1.5) 2.2 9.4 -2.1 (-3.6, -1.5) 4.3 12
miR-26b -1.4 (-3.0, 0.2) -3.1 (-3.4, -1.8) -3.6 (-4.2, -2.8) 3.3 4.7 -0.7 (-2.3, -0.3) 1.7 10
miR-34a -0.2 (-2.1, 0.8) -0.1 (-0.3, 1.0) -0.6 (-2.1, 0.2) -1.1 1.3 -0.1 (-0.9, 0.3) 1.1 6
miR-101 2.5 (1.7, 3.2) 1.6 (1.3, 1.8) 0.4 (-0.3, 0.9) 1.9 4.3 -1.1 (-1.9, -0.6) 2.1 11
miR-132 -1.6 (-2.0, -1.4) -1.7 (-2.1, -1.6) -2.5 (-2.7, -2.2) 1.0 1.8 -0.8 (-1.1, -0.3) 1.7 11
miR-142-3p -2.3 (-4.5, -1.3) -4.4 (-4.5, -3.8) -5.0 (-5.2, -4.5) 4.2 6.2 -0.4 (-1.1, -0.3) 1.4 10
miR-142-5p 3.9 (2.9, 5.7) 3.0 (2.4, 5.5) 1.7 (1.5, 4.3) 1.9 4.7 -1.3 (-1.4, -0.3) 2.4 10
miR-146a -7.3 (-7.5, -6.5) -7.1 (-7.6, -7.0) -7.5 (-7.7, -7.3) -1.2 1.1 -0.5 (-0.8, 0.2) 1.4 8
miR-155 -0.9 (-2.3, 1.5) 0.1 (-0.5, 1.1) -0.5 (-0.7, -0.3) -2.1 -1.4 -0.3 (-1.3, 0.1) 1.2 8
miR-195 -2.5 (-3.0, -1.6) -0.4 (-3.4, 0.2) -2.9 (-4.2, -0.5) -4.6 1.3 -1.1 (-2.0, -0.5) 2.1 11
miR-197 -3.5 (-3.3, -1.3) 0.6 (-1.5, 2.9) 0.6 (-2.5, 2.2) -16.8 -16.5 -0.6 (-2.7, 1.3) 1.5 7
miR-203 2.3 (1.8, 3.0) 3.0 (2.1, 3.0) 2.9 (2.6, 3.4) -1.5 -1.5 0.0 (-0.4, 0.6) 1.0 6
miR-210 3.9 (0.1, 5.0) 3.1 (2.2, 3.4) 1.5 (1.1, 1.8) 1.8 5.1 -1.8 (-2.9, -0.3) 3.4 10
miR-223 -9.3 (-9.6, -8.8) -9.9 (-9.9, -9.6) -10.3 (-10.4, -10.0) 1.5 2.0 -0.4 (-0.6, 0.2) 1.3 6/9a
miR-361 -0.1 (-1.1, 1.1) 2.1 (-0.5, 2.5) 0.6 (-0.2, 0.7) -4.7 -1.7 -1.5 (-2.1, -1.0) 2.9 11
miR-374d -2.2 (-3.4, -2.1) -3.2 (-3.7, -2.0) -4.1 (-4.3, -3.9) 2.0 3.8 -0.6 (-1.0, -0.4) 1.5 12
miR-382 -0.7 (-1.2, 0.5) 1.4 (0.9, 2.7) -0.1 (-1.2, 0.5) -4.1 -1.5 -2.0 (-2.8, -0.8) 4.1 11
miR-454d -1.3 (-2.8, 0.2) -2.3 (-3.2, -0.1) -3.0 (-3.3, -1.3) 1.9 3.3 -0.5 (-1.1, -0.2) 1.4 10
miR-486-3p 4.3 (2.5, 5.6) 4.9 (2.5, 6.2) 3.5 (3.1, 4.3) -1.5 1.8 -2.0 (-3.1, 0.2) 4.1 9
miR-520c-3p 2.3 (0.3, 2.9) -0.4 (-1.6, 2.4) -1.1 (-1.4, 0.5) 6.3 10.6 0.3 (-1.7, 0.6) -1.3 5
miR-579c 4.2 (3.5, 5.0) 3.5 (3.1, 3.7) 2.4 (1.8, 2.9) 1.6 3.6 -1.2 (-1.7, -0.3) 2.2 11
miR-590-3P 5.2 (2.9, 5.8) 3.2 (2.3, 3.9) 2.4 (2.2, 3.1) 3.9 6.9 -0.9 (-1.1, 0.2) 1.9 8
miR-590-5p 1.2 (0.7, 1.4) -0.4 (-1.2, -0.2) -1.3 (-1.6, -0.7) 3.0 5.6 -0.5 (-1.1, -0.3) 1.4 10
miR-598 3.7 (3.1, 4.3) 2.8 (2.5, 3.6) 1.5 (1.4, 1.9) 1.8 4.6 -1.2 (-1.7, -0.8) 2.2 12
miR-628-5p 3.0 (-8.4, 7.9) -7.2 (-8.3, 3.9) -2.9 (-7.8, 2.2) 1174.6 61.3 0.4 (-1.6, 1.7) -1.3 5
miR-15b# 9.9 (2.6, 11.4) 6.2 (5.6, 8.4) 4.0 (2.0, 4.4) 13.3b 58.5b -2.6 (-4.0, -1.8) 6.1b 11/11
miR-335# 6.1 (5.6, 8.3) 6.5 (5.2, 8.1) 4.2 (3.9, 5.1) -1.4b 3.6b -1.9 (-3.9, -1.0) 3.8b 12
microRNA (miRNA) highlighted in bold in matched samples (CCP-VERA) met criteria of median fold change (FC) ≥4 and ≥75% consistent dysregulation.
If fold difference (FD) was < 1, FD = -1/FD. Estimates for each cohort were obtained at the mean age (52 years)
dCt delta cycle threshold, HC healthy controls
aFor 3 patients, Ct values at follow up were extremely low (all ≈ 2, compared to ≈ 14 for the rest); these 3 values were considered to be inaccurate and
in a conservative approach were excluded from analysis
bIn these miRNAs, Ct was > 32 for some healthy controls and CCP+ patients at baseline. As a result, the calculated fold differences and changes may
not be accurate; therefore, these genes were not deemed to have fulfilled our criteria for dysregulation, but were retained for further investigation in
the validation cohort because the calculated FCs were near or above our cutoff, and all progressors showed consistent dysregulation
cIn this miRNA mean FC was >4; miR-579 FC 4.27 (although median FC <4), furthermore consistent dysregulation was seen in 11/12 patients. As custom
cards had capacity for 31 miRNAs to be evaluated these two miRNAs were selected as potentially important
dThe original selection of miR-454 (FD 4.1 between HC-VERA) and miR-374 (FD 4.6 between HC-VERA) from the pilot phase was based on unadjusted
between-group differences; following age-adjustment they no longer met our criteria
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(Additional file 3); however, the FCs were not substantive
(median 1.4 and 1.2 respectively).
Validation phase of serum microRNA profiling
HC-CCP+ (progressor or non-progressor) and HC-VERA
comparison
Between the validation HC group and the validation
CCP+ progressors, two dysregulated (both upregulated)
miRNAs were identified, though not entirely consistent
with the pilot-phase findings, and included miR-22 with
an FD of 11.3. Between the HC group and the VERA
cohort, six upregulated miRNAs were identified
(Additional file 4); four miRNAs were validated from the
pilot results, namely miR-19a, miR-22, miR-590-3p and
miR-598. The inclusion of the CCP+ non-progressor
cohort provided an additional comparison to healthy
status. Only miR-590-3P met the criterion of dysregula-
tion compared to healthy status.
Baseline miRNA profile of progressors vs non-progressors
At baseline, the miRNAs were mostly upregulated in the
progressors compared to the non-progressors, except for
five miRNAs, miR-26b, miR-210, miR-486-3p, miR-590-3p
and miR-628-5p (Additional file 5). Baseline FD between
the two groups for the three miRNAs of interest, miR-22,
miR-382 and miR-486-3p, were 19.7, 2.5 and -1.4, respect-
ively (Table 2).
miRNA change in matched CCP+ to VERA progressor and
matched CCP+ to non-progressor status
Unsupervised hierarchical clustering of the 31 miRNAs
of interest replicating the patient groups studied in the
pilot phase (HC, CCP+ and matched VERA sample)
demonstrated similar clustering as in the pilot phase
(Additional file 6). The 31 miRNAs did not reach our
stringent pre-defined criteria. However, of the three key
miRNAs identified in the pilot phase, miR-486-3p
increased in progressors by a median (IQR) FC of 2.2
(0.4, 6.0) (Additional file 7, Fig. 2a) compared to stable
expression within the non-progressor cohort with a FC
of 1.0 (0.7, 3.0). Whilst the baseline miR-22 FD between
progressors and non-progressors reported earlier was sig-
nificant (19.7), within group interval change, median FC
(IQR), was increased in both progressors (2.5 (0.5, 19.7))
and non-progressors (3.4 (0.5, 12.1)) (Additional file 7,
Fig. 2a). Similar findings were observed with miR-382,
with greater median FC (IQR) in the non-progressor
Fig. 1 Candidate serum miRNA expression profiling. a MicroRNA heatmaps were generated using hierarchical clustering (Gene Cluster 3.0 and
Java TreeView). Green indicates low expression; red indicates high expART ression levels. b Comparison of expression levels of miR-22, miR-382
and miR-486-3p in matched samples from anti-cyclic citrullinated peptide (CCP) + status to very early rheumatoid arthritis (VERA) (medians, 1st
to 3rd quartiles). dCt, delta threshold cycle; HC, healthy controls. Of note, miR-22 was excluded from the healthy control cohort as it was not
expressed in all 12 samples
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cohort (2.4 (1.0, 2.6)) versus progressors (1.2 (0.5, 2.6))
(Additional file 7, Fig. 2a).
Two miRNAs were upregulated from baseline to fol-
low up in the non-progressor but not in the progressor
group,with FC (IQR) miR-203 of 3.1 (0.5, 6.9) vs. -1.1
(0.3, 4.3) and miR-579 of 3.2 (1.0, 3.7) vs. -1.1 (0.3, 3.3),
respectively (Additional file 7, Fig. 2b).
Association with clinical variables
The three miRNAs of interest were substantively associ-
ated (|rho| > 0.3) with the score on the patient disease
activity visual analogue scale (VAS) (Additional file 8).
MiR-382 and 486-3p were both also associated with ten-
der joint count in 28 joints (TJC28) and Disease Activity
Score in 28 joints based on erythrocyte sedimentation
rate (DAS28-ESR).
Predicting progression using baseline miRNAs
Individually, miRs-197 (area under the receiver operat-
ing characteristic curve (AUROC) analysis 0.69, 90% CI
0.52, 0.85) and -335* (AUROC 0.71, 90% CI 0.52, 0.85)
performed better than chance (with 90% confidence);
the recorded areas under the curve (AUCs) were modest
although the upper confidence intervals for several
miRNAs included an AUC= 0.8 (Additional file 5). MiR-22
had sensitivity and specificity of 63% and 100%, respect-
ively, with an AUROC of 0.68 (90% CI 0.48, 0.82), also
demonstrating the highest Youden index, highlighting the
Table 2 Summary: within patient change for CCP+ status to VERA (progression) in both phases and CCP+ status to non-progression
within patient change and vs. progressors from the validation phase















miR-22 4.3 (2.8, 12.1) - - - - - -
miR-382 4.1 (1.7, 6.9) - - -
miR-486-3p 4.1 (0.9, 8.6) - - - - - -
Validation Phase
miR-22 2.5 (-2.2, 15.3) 3.4 (2.3, 12.6) 7.4 (4.1, 8.2) 3.1 (1.8, 7.3) 19.7 0.68 (0.48, 0.82) 63% 100%
miR-382 1.2 (-2.1, 2.7) 2.4 (1.0, 2.6) 1.1 (0.0, 1.8) -0.2 (-0.5, 1.9) 2.5 0.57 (0.40, 0.75) 75% 58%
miR-486-3p 2.2 (-2.5, 6.0) 1.0 (-1.4, 3.0) 3.4 (1.7, 3.9) 3.9 (2.6, 5.0) -1.4 0.55 (0.36, 0.72) 50% 75%
CCP anti-cyclic citrullinated peptide, VERA very early rheumatoid arthritis, miRNA microRNA, FC fold change, FD fold difference, B/L baseline (sample), IQR interquartile
range, ROC receiver operating characteristic, Sens sensitivity, Spec specificity
Fig. 2 Validation-phase serum expression levels of candidate miRNAs. Baseline and follow-up relative expression in the progressor (P) and
non-progressor (NP) cohorts of miR-486-3p, miR-22 and miR-382 (a) and miR-203 and miR-579 (b). HC, healthy controls; dCt, delta cycle threshold
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importance of re-evaluating this in a larger sample size.
MiR-382 and miR-486-3p performed less well, with an
AUROC of 0.57 (0.40, 0.75) and 0.55 (0.36, 0.72), respect-
ively. Table 2 summarises the within-patient change for
CCP+ status to VERA (progression) in both the pilot and
validation phases and within-patient change for CCP+ to
non-progression and non-progression vs. progression in
the validation phase.
Pathway analysis and networking of miRNA target genes
Pathway prediction for the miRNAs of interest was per-
formed, using a bioinformatics approach MetaCore™, to
further elucidate functional processes associated with
selected miRNAs and their targets. The expanded net-
works generated for miRNAs of interest represent pre-
dicted targets (Additional files 9, 10 and 11). Canonical
interaction between the transcription factor p53 and
miR-22 is highlighted; p53 plays a central role in a num-
ber of cellular functions, and is overexpressed in RA
synovial tissue, and also activates miR-22 by binding to
its promoter region [14, 15]. The predicted network
shows that miR-486-3p has an inhibitory effect on bone
morphogenetic protein 1 (BMP-1), indicative of miRNA
function. MiR-382 negatively regulates the phosphatase
and tensin homolog (PTEN), which is upstream of the
AKT/mTOR signalling pathway.
Discussion
This first study of miRNAs in individuals at risk of RA has
identified new miRNAs of interest, which may be associ-
ated with RA initiation and progression from systemic
autoimmunity to disease and may also have a predictive
role in the progression from “at-risk” status to RA.
Current literature reports clinical, serological, imaging
and biological markers either associated with or
potentially predictive of progression from systemic auto-
immunity to RA, such as ACPA, RF, and shared epitope
(SE) fine mapping [16, 17]. Other biomarkers that have
been explored comprise synovial tissue and histology
studies, gene expression analyses and sensitive imaging
[18, 19]. MiRNA studies to date have mainly focused on
peripheral blood and synovial tissue expression in estab-
lished RA, often in minimally defined and heterogeneous
cohorts. Whilst the numbers included in our study are
relatively modest, the benefit of using matched samples
from well-phenotyped individuals (excuding those with
ultrasound-detected synovitis, likely to have already
developed inflammation on a pathophysiological level),
offers a particularly robust and unique approach to
identify miRNA markers of disease initiation and pro-
gression. Our study design initially considered over 700
miRNAs in the pilot phase, followed by a focused valid-
ation phase, enabling us to consider a vast number of
potentially influential miRNAs.
We identified potential roles of miR-22 and -382 and
confirmed the importance of miR-486-3p. Despite these
miRNAs in the validation phase not meeting our strin-
gent criteria; miR-486-3p had an FC > 2, which is of bio-
logical significance particularly since there was stable
expression in the non-progressors. The validation of
miR-22 upregulation in VERA and CCP states compared
to health potentially implicates a role in the develop-
ment of inflammatory disease. Baseline miR-22 was
strongly upregulated in progressors compared to non-
progressors (comparator group) and thus has potential
clinical utility for identifying those that may be at great-
est risk. However, the ROC analysis did not reflect this,
highlighting the need for further evaluation with a larger
patient cohort. Interestingly it has also been identified as
a predictor of response to tumour necrosis factor-
inhibitor therapy [20, 21]. The higher-than-expected FC
of miR-22 and miR-382 within the non-progressors may
reflect an association between this miRNA with ongoing
autoimmunity, which we anticipate, with further follow
up in a proportion of the non-progressors, may manifest
as progression to VERA. Continued evaluation of this
cohort will allow us to address this.
MiR-203 has previously been identified as an miRNA
involved in RA [7], but has not been studied before in
CCP+ at-risk individuals, while miR-579 was upregu-
lated in VERA compared to HC; the significance
however of upregulation in both the cohorts with
inflammation and the CCP+ non-progressors remains
unclear. It is acknowledged that identification of these
two miRNAs is from the comparator group of non-
progressors, and there has been no validation process.
MiRNA-146a and miRNA-155 were only found to be
upregulated in our pilot study with progression to
VERA, conceivably as different miRNAs might be impli-
cated in autoimmunity and disease initiation compared
to miRNAs in established disease. The initial studies
evaluating these miRNAs at the site of disease (synovial
tissue) as opposed to serum might also be relevant.
Conclusions
In summary, we report the first study that has identi-
fied in particular three miRNAs associated with auto-
immunity (at-risk RA) and the progression to RA,
using a unique matched serum sample and compre-
hensive miRNA array approach. Given the associations
between clinical markers and potential predictive
ability, validation of the signature miRNAs as a next
step may offer the opportunity to improve current
models [5] (including evaluation in CCP+, ultrasound
positive cohort), and supports investigation into the
biological functions of the candidate miRNAs through
future network and functional analyses.
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